Financial Performance - Multi Ways Holdings Ltd reported net revenue of $26.44 million for the first half of 2025, representing an increase of 87.65% from $14.09 million in the same period last year [1] - The company's shares rose 59.6% to $0.40 in pre-market trading following the financial results announcement [1] Stock Movements - Indaptus Therapeutics Inc saw a surge of 62.1% to $3.21 after disclosing a significant investment by David E. Lazar [4] - X3 Holdings Co Ltd increased by 43.5% to $0.24 after previously dipping 90% [4] - Northann Corp rose 38.8% to $0.24 after engaging advisory services for business development [4] - Dynavax Technologies Corp gained 37.7% to $15.33 following Sanofi's agreement to acquire the company at $15.50 per share, valuing it at $2.2 billion [4] - Starfighters Space Inc shares jumped 18.2% to $15.30 amid post-IPO volatility [4] - Sidus Space Inc rose 17% to $1.93 after announcing a $25 million offering [4] - UiPath Inc increased by 8.7% to $17.35 after being announced as a member of the S&P Midcap 400 [4] Declines in Stock Prices - Picocela Inc fell 26.1% to $0.27 after a significant increase the previous day [4] - Can Fite Biopharma declined 25% to $0.18 following a reverse share split announcement [4] - Femasys Inc dropped 11.8% to $0.71 after filing a prospectus for a $9.8 million common stock offering [4] - SeaStar Medical Holding Corp fell 9.5% to $0.21 after announcing a reverse split [4] - EUDA Health Holdings Ltd dipped 8.3% to $1.75 after a previous jump of 41% [4]

Group 1: CSX Corp Performance - CSX Corp reported third-quarter revenue of $3.59 billion, exceeding analyst estimates of $3.58 billion [1] - The company achieved adjusted earnings of 44 cents per share, surpassing analyst expectations of 43 cents per share [1] - Following the earnings report, CSX shares increased by 4.2% to $37.51 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Artiva Biotherapeutics Inc gained 98.6% to $5.50 after receiving FDA Fast Track Designation for AlloNK [4] - Safe & Green Holdings Corp surged 38.8% to $4.27 after completing Phase 1 of its intelligent wellsite monitoring system [4] - Kezar Life Sciences Inc rose 36% to $5.67 following a regulatory update on its Zetomipzomib program [4] - INVO Fertility Inc tumbled 34.6% to $0.92 after a significant rise of over 85% the previous day [4] - American Battery Technology Co shares dipped 19.8% to $4.55 after a 37% decline on Thursday due to the termination of a grant by the Department of Energy [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SHF Holdings, Inc. (SHFS) increased by 150% to $8.17 - Lithium Americas Corp. (LAC) rose by 69% to $5.18 - Aqua Metals, Inc. (AQMS) gained 50% reaching $6.11 - CleanCore Solutions, Inc. (ZONE) up by 44% at $2.87 - Cyclerion Therapeutics, Inc. (CYCN) increased by 33% to $4.03 - Twin Vee Powercats Co. (VEEE) rose by 17% to $2.92 - Solidion Technology, Inc. (STI) up by 11% at $5.09 - China Pharma Holdings, Inc. (CPHI) increased by 11% to $2.18 - Stardust Power Inc. (SDST) rose by 10% to $3.04 - Aligos Therapeutics, Inc. (ALGS) increased by 7% to $11.03 [3] Premarket Losers - Aytu BioPharma, Inc. (AYTU) decreased by 15% to $2.11 - Professional Diversity Network, Inc. (IPDN) down by 13% to $4.10 - STRATA Skin Sciences, Inc. (SSKN) fell by 10% to $2.31 - Cohu, Inc. (COHU) decreased by 9% to $20.68 - Super League Enterprise, Inc. (SLE) down by 9% to $7.74 - CTW Cayman (CTW) fell by 9% to $2.29 - Fitell Corporation (FTEL) decreased by 8% to $7.70 - Soluna Holdings, Inc. (SLNH) down by 8% to $2.16 - StableX Technologies, Inc. (SBLX) decreased by 5% to $5.22 - Indaptus Therapeutics, Inc. (INDP) down by 5% to $2.95 [4]

Core Insights - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on innovative therapies for cancer and viral infections [1][3] - The company's chief medical officer, Dr. Roger Waltzman, will moderate a panel at the CMO360 Summit on April 7-8, 2025, discussing clinical trial management [1][2] - Indaptus' approach involves a multi-targeted package of immune system-activating signals delivered intravenously, aiming to enhance both innate and adaptive immune responses [3] Company Overview - Indaptus Therapeutics has developed a patented technology utilizing non-pathogenic Gram-negative bacteria to activate immune responses through various receptors [3] - The Decoy product candidates have shown promise in pre-clinical studies, demonstrating activity against various cancers and chronic viral infections such as hepatitis B and HIV [3] - The company emphasizes the potential for reduced intravenous toxicity while maintaining effective immune activation [3] Industry Context - The CMO360 Summit is recognized as a significant event for biotech Chief Medical Officers, facilitating networking and skill development within the industry [2] - The conference aims to advance efficient medicine development and delivery, highlighting the importance of patient diversity and access in the biotech sector [2]

Core Insights - Indaptus Therapeutics has advanced to a new expansion arm of its Phase 1b/2 clinical trial for Decoy20, evaluating its combination with BeiGene's PD-1 inhibitor, tislelizumab, focusing on safety, dose optimization, and early anti-tumor activity [1][2] Company Overview - Indaptus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections, leveraging a unique Decoy platform that activates the immune system [1][5] - The Decoy platform utilizes non-pathogenic Gram-negative bacteria to produce multiple immune system-activating signals, aiming to enhance both innate and adaptive immune responses [6] Clinical Trial Details - The combination trial will initially involve participants receiving one week of Decoy20 monotherapy before transitioning to the combination treatment with Decoy20 and tislelizumab [7] - The trial will begin with sequential enrollment to monitor safety, followed by unrestricted enrollment after a review by the Safety Review Committee [7] Mechanism of Action - PD-1 inhibitors like tislelizumab block the PD-1 receptor on T cells, allowing the immune system to better combat cancer cells [4] - The combination of checkpoint inhibitors with immune activators like Decoy20 is theorized to provide a more powerful and sustained anti-tumor response [4][2] Preclinical Research Findings - Preclinical studies have shown that Decoy20 can enhance the effectiveness of checkpoint inhibitors, with evidence of tumor eradication in various cancer models [6] - The Decoy platform has demonstrated single-agent activity against multiple cancers and has shown promise in combination with other therapies [6]

Core Insights - Indaptus Therapeutics reported significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort, indicating potential clinical benefits and a favorable safety profile [2][6][7] - The company experienced a decrease in total operating expenses for the fiscal year 2024 compared to 2023, primarily due to reduced research and development costs [4][5][21] - Indaptus has secured new patents in multiple countries and received clinical trial authorization from Health Canada, enhancing its intellectual property and operational capabilities [7][9] Financial Highlights - Research and development expenses for Q4 2024 were $2.5 million, up from $2.0 million in Q4 2023, mainly due to increased costs in the Phase 1 clinical trial [4] - Total operating expenses for the fiscal year 2024 were $15.4 million, a decrease from $16.4 million in 2023, with research and development costs dropping to $7.2 million from $7.6 million [21] - The company reported a net loss of $15.0 million for the fiscal year 2024, compared to a net loss of $15.4 million in 2023, resulting in a loss per share of $1.61, an improvement from $1.83 in the previous year [8][21] Cash Position and Financing - As of December 31, 2024, Indaptus had cash and cash equivalents of $5.8 million, down from $13.4 million at the end of 2023 [9] - The company conducted a private placement in January 2025, generating net proceeds of $2.0 million, and established a $20 million equity line of credit in February 2025 [9] - Net cash used in operating activities for the fiscal year 2024 was $12.3 million, a slight decrease from $13.4 million in 2023 [10][22] Clinical and Corporate Developments - Indaptus is advancing its Phase 1 study of Decoy20 in advanced solid tumors, with plans to initiate a combination trial with BeiGene's PD-1 inhibitor, tislelizumab, expected in 2025 [7][15] - The company presented promising pharmacokinetic and safety results for Decoy20 at major oncology conferences, further validating its clinical approach [7] - Indaptus plans to increase trial sites to accelerate patient enrollment and expects to provide further clinical updates throughout 2025 [15]